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Aripiprazole Induced Severe Parkinsonian Symptoms
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Abstract
Among the next generation of antipsychotics, aripiprazole is the molecule, which has been defined to have a special mode of action,
which is the stabilization of the dopamine system.  Different studies have found the incidence of extrapyramidal symptoms (EPS) with
this antipsychotic to be very much insignificant. Studies done so far have reported the incidence of extrapyramidal side effects to be
equal to that caused by placebo:  here is a case report of a 19 years old female patient suffering from schizophrenic illness, who
developed severe EPS in the form of marked rigidity, tremors, drooling of saliva, masked face, significant hypokinesia and difficulty in
maintaining straight posture after receiving 20 mg of aripiprazole per day. This led to severe disturbance in her routine functioning and
the EPS disappeared within a week after stopping the medicine and administration of anticholinergic drug.
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Introduction
The first antipsychotic drug chlorpromazine was the starting
point of what is rightly called revolution” in the management
of psychosis—particularly schizophrenia. Many compounds
followed which we now know as typical or first generation
antipsychotics. Their unquestionable effect to control
positive symptoms was also associated with significant side
effects—mainly parkinsonism and tardive dyskinesia that
made patients’ life miserable. Besides, they had little effect
on negative symptoms.
After the advent of novel atypical antipsychotics, which
are called as second-generation antipsychotics, namely
clozapine, risperidone, olanzapine, quetiapine & ziprasidone,
the major problem of disturbing extrapyramidal side effects
has been curtailed to a large extent. This is attributed to
their affinity for receptors other than those for dopamine
receptor. They are also effective against negative symptoms.
They, on the other hand are not totally free of side effects
like weight gain, bone marrow depression, seizures, QT
prolongation etc. With higher doses, risperidone causes EPS
similar to typical antipsychotics. Search for ideal
antipsychotic is still on and we keep seeing newer and
newer molecules in the market with different claims. One
such molecule is aripiprazole which is already being claimed
as third generation antipsychotic because of its supposedly
different mechanism of action which is called stabilization
of dopamine system (Stahl, 2000) .It is a D2 receptor partial
agonist with partial agonist activity at serotonin 5HT1A
receptors. Based on this “unique”mechanism of partial
agonist action, it is claimed to have minimal or non-significant
motor side effects (Petrie et al, 1998).
We report a case of severe EPS with the use of
aripriprazole, which lead to discontinuation of it.
Case Report:
H.K., 19 years old unmarried female presented  with 6
months old  psychotic illness characterized by unmanageable
agitation, hallucinatory behaviour, loosening of associations,
delusions of parasitosis, persecution , reference and labile
mood. She was receiving alprazolam 1 mg/day, olanzapine
5 mg/day and amoxapine 100 mg/day from a general
physician. After detailed work-up, diagnosis of paranoid
schizophrenia (ICD-10) was made.  She was put on
aripiprazole 15 mg/day. Olanzapine and amoxapine were
stopped and alprazolam was replaced with clonazepam 2mg
per day in divided doses.
After 1 week, she reported improvement in sleep and
decline in agitation but still had significant psychotic features.
Dose of aripiprazole was increased to 20 mg/day and
clonazepam was continued as before. Four days later she
developed severe EPS.  Patient had marked rigidity, resting
tremors, slurred speech which was almost incomprehensible,
significant hypokinesia, short sluggish gait, drooling of saliva,
difficulty in maintaining straight posture & marked
incapacitation. Aripiprazole was stopped .She was given
inj. promethazine 50 mg i.m. and was put on trihexyphenidyl
6 mg/day. After 7 days, patient was almost completely free
of the parkinsonian symptoms.175
Discussion:
As per literature available so far regarding EPS related
adverse events, the incidence with aripirazone has been
found to be very much insignificant.  This is a drug under
the new class of antipsychotics: Dopamine System Stabilizer
(DSS).  It has been referred to as partial agonist at D2
receptor because of which it exhibits functional dopamine
antagonism at hyperactive dopamine neurons & agonistic
action under hypodopaminergic condition (Burris et al.,
2002). It has been suggested that DSS do not decrease
dopamine activity where dopamine level is needed (nigro-
striatal pathway) and thus do not cause motor side effects
(Stahl, 2001).
The new concept of dopamine system stabilization is
considered not to induce motor side effects. Incidence of
extrapyramidal adverse events with aripirazole (30mg/day)
is just comparable with placebo 20% and 21% respectively
(Kane et al., 2002,).  Another study compairing aripiprazole
(20 mg/day, 30mg/day) with risperidone (6mg/day) has found
almost similar incidence of EPS related adverse effects in
both the group which was statistically not significantly
different from placebo group (Potkin et al., 2003).
Theoretical explanations seem quite encouraging but so far
there are only few well designed studies to evaluate its
efficacy and adverse effects. Why, the drugs which are
claimed to be safe and well tolerable show different results
when they come into practical use, brings out an issue which
needs due consideration. The conclusions that are derived
from the reports provided by the surveys and research
conducted or sponsored by the pharmaceutical companies,
there is every possibility of getting the results biased. Indian
group of population responding differently to these molecules
can be another reason for having such events. Clinical
experience will certainly clear the mist surrounding the new
drug and its proposed unconventional mode of action will
also be tested by sound scientific research. Though it is a
single case report, yet it cannot be ignored as the drug has
just been introduced in the Indian market. It seems that we
have still to go a long way in search of an ideal antipsychotic.
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